[Drug therapy for small-cell lung cancer (SCLC)--new molecular strategies for therapy]. / Medikamentöse Therapie des kleinzelligen Bronchialkarzinoms (SCLC)--neue molekulare Therapieansätze.
Pneumologie
; 62(1): 23-30, 2008 Jan.
Article
en De
| MEDLINE
| ID: mdl-17948174
ABSTRACT
Small-cell lung cancer accounts for up to 20 % of lung cancer and is the most aggressive type. Although responding to chemotherapy, it often relapses early. In spite of more than thirty years of intensive research, its prognosis has not been improved. Through increasing knowledge about molecular mechanisms and the involved genes, translational research into antibodies, small molecules and even vaccines, might result in interesting new strategies for the near future. After a short introduction about the function of the relevant genes, the diagnostic and prognostic value will be described. In the second part of this review the focus will lie on current studies (mostly phases I and II) for the treatment of SCLC.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Sistemas de Liberación de Medicamentos
/
Carcinoma de Células Pequeñas
/
Vacunas contra el Cáncer
/
Neoplasias Pulmonares
/
Antineoplásicos
Límite:
Humans
Idioma:
De
Revista:
Pneumologie
Año:
2008
Tipo del documento:
Article